Scarica l'app Stockscreener
4.19
3.46%
-0.15
Dopo l'orario di chiusura:
4.17
-0.02
-0.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FHTX Giù?
Forum
Previsione
Precedente Chiudi:
$4.34
Aprire:
$4.4
Volume 24 ore:
116.47K
Relative Volume:
0.80
Capitalizzazione di mercato:
$233.02M
Reddito:
$34.16M
Utile/perdita netta:
$-98.43M
Rapporto P/E:
-1.7906
EPS:
-2.34
Flusso di cassa netto:
$-119.33M
1 W Prestazione:
+3.20%
1M Prestazione:
-11.23%
6M Prestazione:
-40.31%
1 anno Prestazione:
+31.76%
Intervallo 1D:
$4.05
$4.64
Intervallo di 1 settimana:
$3.86
$4.64
Portata 52W:
$2.70
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Nome
Foghorn Therapeutics Inc
Settore
Industria
Telefono
617-586-3100
Indirizzo
500 TECHNOLOGY SQUARE, CAMBRIDGE
Confronta FHTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.19 | 233.02M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-03 | Iniziato | Jefferies | Buy |
| 2024-08-19 | Iniziato | Evercore ISI | Outperform |
| 2023-03-28 | Iniziato | BofA Securities | Buy |
| 2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-22 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-17 | Iniziato | Cowen | Outperform |
| 2020-11-17 | Iniziato | Goldman | Buy |
| 2020-11-17 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-17 | Iniziato | Wedbush | Outperform |
Mostra tutto
Foghorn Therapeutics Inc Borsa (FHTX) Ultime notizie
B. Riley Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to "Strong-Buy" - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Upgraded at B. Riley - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Coverage Initiated by Analysts at B. Riley - MarketBeat
Foghorn Therapeutics a new buy at B Riley on tumor fighting technology - Seeking Alpha
This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
B. Riley Initiates Foghorn Therapeutics at Buy With $10 Price Target -January 30, 2025 at 07:56 am EST - Marketscreener.com
Foghorn Therapeutics receives Nasdaq compliance notice - MSN
Foghorn Therapeutics receives Nasdaq compliance notice By Investing.com - Investing.com Australia
Foghorn Therapeutics (FHTX) Stock Price, News & Analysis - MarketBeat
Barclays PLC Grows Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know - MSN
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Sold by Jane Street Group LLC - Defense World
Foghorn Therapeutics Sets 2025 Strategic Objectives - TipRanks
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025 - The Manila Times
Foghorn Therapeutics Advances Cancer Drug Pipeline, Secures Runway into 2027 with $243.8M Cash - StockTitan
Barclays PLC Acquires 26,228 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Bought by Geode Capital Management LLC - Defense World
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Expands By 6.8% - MarketBeat
More Unpleasant Surprises Could Be In Store For Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares After Tumbling 41% - Simply Wall St
Foghorn Therapeutics announces director resignation - Investing.com India
Foghorn Therapeutics announces director resignation By Investing.com - Investing.com Nigeria
Foghorn Therapeutics Board Member Resignation Announced - TipRanks
State Street Corp Grows Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
XTX Topco Ltd Buys Shares of 10,900 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
FY2028 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World
HC Wainwright Has Positive Forecast for FHTX FY2024 Earnings - Defense World
Charles Schwab Investment Management Inc. Grows Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Wedbush Reduces Earnings Estimates for Foghorn Therapeutics - MarketBeat
HC Wainwright Issues Optimistic Estimate for FHTX Earnings - MarketBeat
Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright - Yahoo Finance
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Decreases By 9.7% - MarketBeat
Foghorn Therapeutics shares target cut, buy rating on positive outlook By Investing.com - Investing.com Canada
Foghorn Therapeutics (NASDAQ:FHTX) Given New $14.00 Price Target at Jefferies Financial Group - Defense World
Foghorn Therapeutics' (FHTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Foghorn Therapeutics Advances Precision Oncology Pipeline - Yahoo Finance
Foghorn Therapeutics Stock Slides On Cancer Drug Development Halt, But Retail Remains Upbeat - Asianet Newsable
Foghorn Therapeutics' SWOT analysis: chromatin pioneer's stock faces pivotal moment - Investing.com Canada
Foghorn Therapeutics Inc Azioni (FHTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):